Treatment of cachexia: An overview of recent developments

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 736-742

  Von Haehling, Stephan ^a,b   Anker, Stefan D ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cachexia; Cancer; Therapy; Wasting

Indexed keywords

ANABOLIC AGENT; APPETITE STIMULANT; CARNITINE; ENOBOSARM; FORMOTEROL; GHRELIN; MEGESTROL ACETATE; MELATONIN; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; TESTOSTERONE; THALIDOMIDE;

BODY COMPOSITION; BODY MASS; CACHEXIA; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; ENERGY EXPENDITURE; GRIP STRENGTH; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NUTRITIONAL SUPPORT; PATIENT CARE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT INDICATION; WALKING; DRUG EFFECTS; KINESIOTHERAPY; MUSCLE STRENGTH; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKELETAL MUSCLE; TREATMENT OUTCOME; TRENDS;

APPETITE STIMULANTS; CACHEXIA; EXERCISE THERAPY; HUMANS; MUSCLE STRENGTH; MUSCLE, SKELETAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84933523187     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.10.026     Document Type: Article

References (83)

1. S. von Haehling, S.D. Anker, Cachexia vs obesity: Where is the real unmet clinical need? J Cachex Sarcopenia Muscle 4 (2013) 245-246.
2. V.C. Vaughan, P. Martin, P.A. Lewandowski, Cancer cachexia: Impact, mechanisms and emerging treatments, J Cachex Sarcopenia Muscle 4 (2013) 95-109.
3. S. von Haehling, S.D. Anker, Cachexia as amajor underestimated and unmet medical need: facts and numbers, J Cachex Sarcopenia Muscle 1 (2010) 1-5.
4. W.J. Evans, J.E. Morley, J. Argilés, et al., Cachexia: A new definition, Clin Nutr 27 (2008) 793-799.
5. J. Farkas, S. von Haehling, K. Kalantar-Zadeh, J.E. Morley, S.D. Anker, M. Lainscak, Cachexia as a major public health problem: frequent, costly, and deadly, J Cachex Sarcopenia Muscle 4 (2013) 173-178.
6. J.E. Morley, A.M. Abbatecola, J.M. Argiles, et al., Sarcopenia with limited mobility: An international consensus, J Am Med Dir Assoc 12 (2011) 403-409.
7. S. von Haehling, J.E. Morley, S.D. Anker, From muscle wasting to sarcopenia and myopenia: update 2012, J Cachex Sarcopenia Muscle 3 (2012) 213-217.
8. D.R. Alchin, Sarcopenia: describing rather than defining a condition, J. Cachexia Sarcopenia Muscle 5 (2014) 265-268.
9. K. Fearon, W.J. Evans, S.D. Anker, Myopenia-a new universal term for muscle wasting, J Cachex Sarcopenia Muscle 2 (2011) 1-3.
10. S.D. Anker, A.J. Coats, J.E.Morley, et al., Muscle wasting disease: A proposal for a new disease classification, J Cachex Sarcopenia Muscle 5 (2014) 1-3.
11. K. Sakuma, A. Yamaguchi, Sarcopenia and cachexia: The adaptations of negative regulators of skeletal muscle mass, J Cachex Sarcopenia Muscle 3 (2012) 77-94.
12. M.J. Ormsbee, C.M. Prado, J.Z. Ilich, S. Purcell, M. Siervo, A. Folsom, L. Panton, Osteosarcopenic obesity: The role of bone, muscle, and fat on health, J. Cachexia Sarcopenia Muscle 5 (2014) 183-192.
13. F.E. Pedroso, P.B. Spalding, M.C. Cheung, et al., Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia, J Cachex Sarcopenia Muscle 3 (2012) 199-211.
14. E. Ferraro, F.Molinari, L. Berghella, Molecular control of neuromuscular junction development, J Cachex Sarcopenia Muscle 3 (2012) 199-211.
15. J.E. Morley, S. von Haehling, S.D. Anker, Are we closer to having drugs to treat muscle wasting disease? J Cachex Sarcopenia Muscle 5 (2014) 83-87.
16. V. Malafarina, F. Uriz-Otano, R. Iniesta, L. Gil-Guerrero, Effectiveness of nutritional supplementation onmusclemass in treatment of sarcopenia in old age: A systematic review, J Am Med Dir Assoc 14 (2013) 10-17.
17. S. von Haehling, M. Lainscak, J. Springer, S.D. Anker, Cardiac cachexia: A systematic overview, Pharmacol Ther 121 (2009) 227-252.
18. S. Busquets, M. Toledo, M. Orpí, et al., Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance, J Cachex Sarcopenia Muscle 3 (2012) 37-43.
19. K.A. Mirza, S.L. Pereira, N.K. Edens, M.J. Tisdale, Attenuation of muscle wasting in murine C2C 12myotubes by epigallocatechin-3-gallate, J. Cachexia Sarcopenia Muscle 5 (2014) 339-345.
20. A. Tschirner, S. von Haehling, S. Palus, W. Doehner, S.D. Anker, J. Springer, Ursodeoxycholic acid treatment in a rat model of cancer cachexia, J Cachex Sarcopenia Muscle 3 (2012) 31-36.
21. H. Der-Torossian, A. Wysong, S. Shadfar, M.S. Willis, J. McDunn, M.E. Couch, Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia, J Cachex Sarcopenia Muscle 4 (2013) 145-155.
22. T.S. Solheim, P.M. Fayers, T. Fladvad, et al., Is there a genetic cause of appetite loss? -an explorative study in 1, 853 cancer patients, J Cachex Sarcopenia Muscle 3 (2012) 191-198.
23. C.R. Tan, P.M. Yaffee, L.H. Jamil, et al., Pancreatic cancer cachexia: A review of mechanisms and therapeutics, Front Physiol 5 (2014) 88.
24. V.W. Tsai, Y. Husaini, R. Manandhar, et al., Anorexia/cachexia of chronic diseases: A role for the TGF-β family cytokine MIC-1/GDF15, J Cachex Sarcopenia Muscle 3 (2012) 239-243.
25. S. Soenen, I.M. Chapman, Bodyweight, anorexia, and undernutrition in older people, J Am Med Dir Assoc 14 (2013) 642-648.
26. J.M. Argilés, A. Anguera, B. Stemmler, A new look at an old drug for the treatment of cancer cachexia: megestrol acetate, Clin Nutr 32 (2013) 319-324.
27. H.S. Wen, X. Li, Y.Z. Cao, et al., Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide, Chemotherapy 58 (2012) 461-467.
28. C.A. Greig, N. Johns, C. Gray, et al., Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy, Support Care Cancer 22 (2014) 1269-1275.
29. R. Silvério, A. Laviano, F. Rossi Fanelli, M. Seelaender, L-Carnitine and cancer cachexia: clinical and experimental aspects, J Cachex Sarcopenia Muscle 2 (2011) 37-44.
30. C. Madeddu, M. Dessì, F. Panzone, et al., Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome, Clin Nutr 31 (2012) 176-182.
31. M. Kraft, K. Kraft, S. Gärtner, et al., L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - A randomized multicentre trial, Nutr J 11 (2012) 52.
32. G.D. Cuvelier, T.J. Baker, E.F. Peddie, et al., A randomized, double-blind, placebocontrolled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy, Pediatr Blood Cancer 61 (2014) 672-679.
33. V. Raghavendra, S.K. Kulkarni, Melatonin reversal of DOI-induced hypophagia in rats; possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of HPA axis, Brain Res 860 (2000) 112-118.
34. F. Del Fabbro, R. Dev, D. Hui, L. Palmer, E. Bruera, Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: A doubleblind placebo-controlled trial, J Clin Oncol 31 (2013) 1271-1276.
35. D.S. Hong, D. Hui, E. Bruera, et al., MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: An open-label, phase 1 doseescalation and expansion study, Lancet Oncol 15 (2014) 656-666.
36. T. Eriksson, S. Bjorkman, P. Hoglund, Clinical pharmacology of thalidomide, Eur J Clin Pharmacol 57 (2001) 365-376.
37. E.P. Sampaio, G. Kaplan, A. Miranda, et al., The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum, J Infect Dis 168 (1993) 408-414.
38. S. Yennurajalingam, J.S. Willey, J.L. Palmer, et al., The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: Results of a double-blind placebo-controlled randomized study, J Palliat Care 15 (2012) 1059-1064.
39. M. Davis, W. Lasheen, D. Walsh, F. Mahmoud, L. Bicanovsky, R. Lagman, A phase II dose titration study of thalidomide for cancer-associated anorexia, J Pain Symptom Manage 43 (2012) 78-86.
40. R.H. Mak, A.T. Ikizler, C.P. Kovesdy, D.S. Raj, P. Stenvinkel, K. Kalantar-Zadeh, Wasting in chronic kidney disease, J Cachex Sarcopenia Muscle 2 (2011) 9-25.
41. M. Rattanasompattikul, M.Z. Molnar, M.L. Lee, et al., Anti-inflammatory and antioxidative nutrition in hypoalbuminemic dialysis patients (AIONID) study: Results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial, J Cachex Sarcopenia Muscle 4 (2013) 247-257.
42. H.Wakabayashi, K. Sakuma, Rehabilitation nutrition for sarcopeniawith disability: A combination of both rehabilitation and nutrition care management, J. Cachexia Sarcopenia Muscle 5 (2014) 269-277.
43. Steinbeck von Haehling, W. Doehner, J. Springer, S.D. Anker, Musclewasting in heart failure: An overview, Int J Biochem Cell Biol 45 (2013) 2257-2265.
44. Z. Jarkovska, M. Krsek, M. Rosicka, J. Marek, Endocrine and metabolic activities of a recently isolated peptide hormone ghrelin, an endogenous ligand of the growth hormone secretagogue receptor, Endocr Regul 38 (2004) 80-86.
45. A. Fanzani, V.M. Conraads, F. Penna, W. Martinet, Molecular and cellular mechanisms of skeletal muscle atrophy: An update, J Cachex Sarcopenia Muscle 3 (2012) 163-179.
46. T. Akamizu, K. Kangawa, Ghrelin for cachexia, J Cachex Sarcopenia Muscle 1 (2010) 169-176.
47. I. Wolf, S. Sadetzki, H. Kanety, et al., Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients, Cancer 106 (2006) 966-973.
48. K. Norman, N. Stobäus, J. Reiß, J. Schulzke, L. Valentini, M. Pirlich, Effect of sexual dimorphism on muscle strength in cachexia, J Cachex Sarcopenia Muscle 3 (2012) 111-116.
49. B.O. Burney, J.M. Garcia, Hypogonadismin male cancer patients, J Cachex Sarcopenia Muscle 3 (2012) 149-155.
50. K. Lenk, S. Palus, R. Schur, et al., Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model, J Cachex Sarcopenia Muscle 4 (2013) 63-69.
51. M. Knops, C.G. Werner, N. Scherbakov, et al., Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: The rationale and design of the Body Size in Stroke Study (BoSSS), J Cachex Sarcopenia Muscle 4 (2013) 199-207.
52. I. Legakis, J. Stathopoulos, T. Matzouridis, G.P. Stathopoulos, Decreased plasma ghrelin levels in patients with advanced cancer and weight loss in comparison to healthy individuals, Anticancer Res 29 (2009) 3949-3952.
53. K. Barao, T.D. Silva, G.A. Osorio, M.A. Vicente, L.M. Oyama, N.M. Forones, The behaviour of the peptides leptin and ghrelin, PYY, NPY, CART and MSH in gastric cancer patients, J Cachex Sarcopenia Muscle 3 (2012) 281-301.
54. A.J. Coats, Research on cachexia, sarcopenia and skeletal muscle in cardiology, J Cachex Sarcopenia Muscle 3 (2012) 219-223.
55. N. Nagaya, J.Moriya, Y. Yasumura, et al., Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure, Circulation 110 (2004) 3674-3679.
56. N. Nagaya, T. Itoh, S. Murakami, et al., Treatment of cachexiawith ghrelin in patients with COPD, Chest 128 (2005) 1187-1193.
57. J.M. Garcia, C. Graham, K.W.P. Kumor, A phase II, randomized, placebo-controlled, double blind study of the efficacy and safety of RC-1291 for the treatment of cancer-cachexia, J Clin Oncol 25 (2007) S25 [Abstract].
58. N.M. Neary, C.J. Small, A.M. Wren, et al., Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial, J Clin Endocrinol Metab 89 (2004) 2832-2836.
59. F. Strasser, T.A. Lutz, M.T. Maeder, et al., Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: A randomised, placebocontrolled, double-blind, double-crossover study, Br J Cancer 98 (2008) 300-308.
60. K. Wynne, K. Giannitsopoulou, C.J. Small, et al., Subcutaneous ghrelin enhances acute food intake inmalnourished patients who receive maintenance peritoneal dialysis: A randomized, placebo-controlled trial, J Am Soc Nephrol 16 (2005) 2111-2118.
61. D.R. Ashby, H.E. Ford, K.J. Wynne, et al., Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment, Kidney Int 76 (2009) 199-206.
62. K. Miki, R. Maekura, N. Nagaya, et al., Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: A multicenter, randomized, double-blind, placebo-controlled trial, PLoS One 7 (2012) e35708.
63. J. Temel, S. Bondarde, M. Jain, et al., Efficacy and safety results from a phase II study of anamorelin HCl, a ghrelin receptor agonist, in NSCLC patients, J Cachex Sarcopenia Muscle 4 (2013) 295-343 [Abstract 5-01].
64. A. Abernethy, J. Temel, D. Currow, L. Gleich, J. Friend, Anamorelin HCl for the treatment of anorexia-cachexia in lung cancer: Study design and baseline characteristics of patients in the phase III clinical trial ROMANA 2 (HT-ANAM-302), J Cachex Sarcopenia Muscle 4 (2013) 295-343 [Abstract 5-02].
65. J.M. Garcia, J. Friend, S. Allen, Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: A multicenter, randomized, double-blind, crossover, pilot study, Support Care Cancer 21 (2013) 129-137.
66. G. Caminiti, M. Volterrani, F. Iellamo, et al., Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study, J Am Coll Cardiol 54 (2009) 919-927.
67. F. Iellamo, M. Volterrani, G. Caminiti, et al., Testosterone therapy in women with chronic heart failure: A pilot double-blind, randomized, placebo-controlled study, J Am Coll Cardiol 56 (2010) 1310-1316.
68. S. Fülster, M. Tacke, A. Sandek, et al., Muscle wasting in patients with chronic heart failure: Results from the studies investigating co-morbidities aggravating heart failure (SICA-HF), Eur Heart J 34 (2013) 512-519.
69. S.D. Anker, T.P. Chua, P. Ponikowski, et al., Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia, Circulation 96 (1997) 526-534.
70. E.A. Jankowska, P. Rozentryt, B. Ponikowska, et al., Circulating estradiol and mortality in men with systolic chronic heart failure, JAMA 301 (2009) 1892-1901.
71. N. Ebner, C.G. Werner, W. Doehner, S.D. Anker, S. von Haehling, Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference, J Cachex Sarcopenia Muscle 3 (2012) 45-50.
72. N. Ebner, J. Springer, K. Kalantar-Zadeh, et al., Mechanism and novel therapeutic approaches to wasting in chronic disease, Maturitas 75 (2013) 199-206.
73. J.T. Dalton, K.G. Barnette, C.E. Bohl, et al., The selective androgen receptor modulator GTx-024 (enobosarm) improves lean bodymass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebocontrolled phase II trial, J Cachex Sarcopenia Muscle 2 (2011) 153-161.
74. J.E.Morley, S.D. Anker, S. von Haehling, Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014, J. Cachexia Sarcopenia Muscle 5 (2014) 253-259.
75. A. Nedergaard, S. Sun, M.A. Karsdal, et al., Type VI collagen turnover-related peptides-novel serological biomarkers of muscle mass and anabolic response to loading in young men, J Cachex Sarcopenia Muscle 4 (2013) 267-275.
76. A.S. Dobs, R.V. Boccia, C.C. Croot, et al., Effects of enobosarm on muscle wasting and physical function in patients with cancer: A double-blind, randomised controlled phase 2 trial, Lancet Oncol 14 (2013) 335-345.
77. J. Crawford, J.T. Dalton, M.L. Hancock, M.A. Johnston, Steiner M. Enobosarm, A selective androgen receptor modulator (SARM), increases lean body mass (LBM) in advanced non-small cell lung cancer patients in two pivotal, international phase 3 trials, J Cachex Sarcopenia Muscle 5 (2014) 35-78 [Abstract 5-15].
78. E. Del Fabbro, J.M. Garcia, R. Dev, et al., Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: A preliminary double-blind placebo-controlled trial, Support Care Cancer 21 (2013) 2599-2607.
79. A.J. Stewart Coats, V. Srinivasan, J. Surendran, et al., The ACT-ONE trial, amulticentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: Study design, J Cachex Sarcopenia Muscle 24 (2011) 201-207.
80. M.S. Pötsch, A. Tschirner, S. Palus, et al., The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats, J Cachex Sarcopenia Muscle 52 (2014) 149-158.
81. Hartmann K. Palus, T. Braun, A. Tschirner, et al., Beta-blocker for the treatment of cancer cachexia: Are they all equal? J Cachex Sarcopenia Muscle 5 (2014) 35-78 [63 (Abstract 4-19)].
82. Stewart Coats, H.G. Fuang, K. Prabhash, et al., Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer (ACT-ONE): Randomised, double-blind, placebo-controlled, international multi-centre phase II study, J Cachex Sarcopenia Muscle 5 (2014) 35-78 [Abstract 5-19].
83. N. Ebner, L. Steinbeck, W. Doehner, S.D. Anker, S. von Haehling, Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies, J Cachex Sarcopenia Muscle 5 (2014) 27-34.